Iodine brachytherapy as an alternative to enucleation for large uveal melanomas

Puusaari, Ilkka; Heikkonen, Jorma; Summanen, Paula; Tarkkanen, Ahti; Kivelä, Tero

doi:10.1016/s0161-6420(03)00661-4

Cited by 96 publications

(76 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Alternative treatments include brachytherapy [14,25,26], gamma-knife radiosurgery [27], proton beam radiation [28,29], fractionated stereotactic radiotherapy [30,31], and partial lamellar sclerouvectomy [32]. However, none of these alternative therapies has been evaluated prospectively.…”

Section: Discussionmentioning

confidence: 99%

Ruthenium-106 brachytherapy for thick uveal melanoma: reappraisal of apex and base dose radiation and dose rate

Naseripour¹,

Jaberi²,

Sedaghat³

et al. 2016

jcb

View full text Add to dashboard Cite

Purpose: To evaluate the outcomes of ruthenium-106 ( 106 Ru) brachytherapy in terms of radiation parameters in patients with thick uveal melanomas.Material and methods: Medical records of 51 patients with thick (thickness ≥ 7 mm and < 11 mm) uveal melanoma treated with 106 Ru brachytherapy during a ten-year period were reviewed. Radiation parameters, tumor regression, best corrected visual acuity (BCVA), and treatment-related complications were assessed.Results: Fifty one eyes of 51 consecutive patients including 25 men and 26 women with a mean age of 50.5 ± 15.2 years were enrolled. Patients were followed for 36.1 ± 26.5 months (mean ± SD). Mean radiation dose to tumor apex and to sclera were 71 (± 19.2) Gy and 1269 (± 168.2) Gy. Radiation dose rates to tumor apex and to sclera were 0.37 (± 0.14) Gy/h and 6.44 (± 1.50) Gy/h. Globe preservation was achieved in 82.4%. Preoperative mean tumor thickness of 8.1 (± 0.9) mm decreased to 4.5 (± 1.6) mm, 3.4 (± 1.4) mm, and 3.0 (± 1.46) mm at 12, 24, and 48 months after brachytherapy (p = 0.03). Four eyes that did not show regression after 6 months of brachytherapy were enucleated. Secondary enucleation was performed in 5 eyes because of tumor recurrence or neovascular glaucoma. Tumor recurrence was evident in 6 (11.8%) patients. Mean Log MAR (magnification requirement) visual acuity declined from 0.75 (± 0.63) to 0.94 (± 0.5) (p = 0.04). Best corrected visual acuity of 20/200 or worse was recorded in 37% of the patients at the time of diagnosis and 61.7% of the patients at last exam (p = 0.04). Non-proliferative and proliferative radiation-induced retinopathy was observed in 20 and 7 eyes.Conclusions: Thick uveal melanomas are amenable to 106 Ru brachytherapy with less than recommended apex radiation dose and dose rates.

show abstract

Section: Discussionmentioning

confidence: 99%

Ruthenium-106 brachytherapy for thick uveal melanoma: reappraisal of apex and base dose radiation and dose rate

Naseripour¹,

Jaberi²,

Sedaghat³

et al. 2016

jcb

View full text Add to dashboard Cite

show abstract

“…Five-year unadjusted survival rates for the two therapies were comparable, at slightly better than 80% for both. 32 The COMS and other recent trials have shown that iodine-125 brachytherapy provides survival rates equal to enucleation for both medium 27 and large 33,34 choroidal melanomas, providing reliable data when alternative treatment methods are discussed with patients.…”

Section: Radiotherapymentioning

confidence: 97%

Choroidal Melanoma: Natural History and Management Options

Bell

Wilson

2004

Cancer Control

View full text Add to dashboard Cite

“…There have been no clinical trials evaluating the effectiveness of therapies other than enucleation for large melanomas. 33 A major criticism of the COMS is that its primary findings essentially confirm what was strongly suspected but never proven 15 years ago -that for medium-size choroidal melanomas, there is no difference in survival benefit between brachytherapy or enucleation. The argument that the cost and the length of time to complete the COMS used limited national resources needed for the development of more promising therapies or for the advancement of basic research into melanoma biology is no longer relevant.…”

Section: Discussionmentioning

confidence: 99%

The Collaborative Ocular Melanoma Study: An Overview

Margo

2004

Cancer Control

119

View full text Add to dashboard Cite

Melanoma of the choroid is an uncommon malignancy, occurring in approximately 6 individuals per million population annually, or approximately 1,400 new cases in the United States each year. 1 The incidence of choroidal melanoma is about one tenth that of cutaneous melanoma, but unlike skin melanoma, its incidence has remained fairly stable. 2,3 The mean age at diagnosis is the mid 50s. 1 Choroidal melanomas are rare among nonwhites. 4,5 Other than an infrequent report of family cluster, choroidal melanoma occurs sporadically.

show abstract

Iodine brachytherapy as an alternative to enucleation for large uveal melanomas

Cited by 96 publications

References 33 publications

Ruthenium-106 brachytherapy for thick uveal melanoma: reappraisal of apex and base dose radiation and dose rate

Ruthenium-106 brachytherapy for thick uveal melanoma: reappraisal of apex and base dose radiation and dose rate

Choroidal Melanoma: Natural History and Management Options

The Collaborative Ocular Melanoma Study: An Overview

Contact Info

Product

Resources

About